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myocardial adenosine system may be a novel therapeutic 
target.[7]
Dipyridamole (DIP) is an inhibitor of  the adenosine 
transporter that increases adenosine levels.[8] DIP 
therapy has improved symptoms, exercise capacity, and 
left ventricular (LV) function in observational, small 
studies on patients with HF;[9-11] the PRoFESS study for 
secondary prevention of  stroke observed a reduction in 
HF in the arm randomized to acetylsalicylic acid (ASA) 
plus DIP as compared to the one randomized to 
clopidogrel.[12]
INTRODUCTION
Heart failure (HF) is a major cause of  morbidity 
and mortality[1,2] so that the understanding of  its 
pathophysiology is crucial to develop new therapeutic 
strategies. In HF, elevation of  plasma adenosine is present.[3] 
Adenosine exerts protective actions in the failing heart.[4,5] 
Increased levels may be a compensatory mechanism, and a 
further elevation might be beneficial.[6] Modulation of  the 
Address for correspondence: 
Dr. Francesco Stea, Institute of Clinical Physiology, National 
Research Council, Via Moruzzi 1, 56124 Pisa (LI), Italy. 
E-mail: francescostea@inventati.org
Access this article online
Quick Response Code:
Website: 
www.pnrjournal.com
DOI:  
10.4103/0976-9234.177076 
How to cite this article: Stea F, Havasi K, Sicari R, Rózsavölgyi Z, 
Morales MA, Somfay A, et al. Dipyridamole in heart failure due to dilated 
cardiomyopathy: A pilot study. J Pharm Negative Results 2016;7:46-52.
This is an open access article distributed under the terms of the Creative 
Commons Attribution-NonCommercial-ShareAlike 3.0 License, which allows 
others to remix, tweak, and build upon the work non-commercially, as long as the 
author is credited and the new creations are licensed under the identical terms.
For reprints contact: reprints@medknow.com
Abstract
Introduction: Dipyridamole (DIP) might be beneficial in heart failure (HF). It 
has been reported to improve symptoms in observational, small‑scale studies. The 
PRoFESS study for secondary prevention of stroke observed a reduction in the risk 
of HF with acetylsalicylic acid (ASA) plus DIP in comparison with clopidogrel. The 
present pilot study was aimed at assessing the clinical effects of DIP and ASA in dilated 
cardiomyopathy. Materials and Methods: Nineteen outpatients with nonischemic 
HF, New York Heart Association (NYHA) Class II, ejection fraction (EF) <40%, 
were randomized to ASA 25 mg, or ASA 25 mg plus DIP 200 mg (ASA + DIP), 
twice daily. They were evaluated at baseline and after 6 months for symptoms, EF, and 
exercise capacity through 6‑min walk test. Results: Eleven subjects were in the ASA 
group and 8 in the ASA + DIP. Dyspnea improved, without differences between the 
two arms: n = 6/5/0/0 for NYHA I/II/III/IV in ASA, n = 4/3/1/0 in ASA + DIP. EF 
increased in both groups (ASA: from 34 [28–35%] to 40 [32–46%]; ASA + DIP from 
32.5 [25.75–34%] to 36 [31.5–46%]). No change in meters walked or points in the 
Borg scale was observed. In a similar population, an adequately powered study would 
need to recruit 38 subjects. Conclusion: The study, although underpowered, did not 
show any difference between the two treatment strategies. While this appears in contrast 
with previous studies, the strict inclusion criteria, the randomized, double‑blind design, 
and the clinical end‑points give strength to our findings. A properly sized trial would 
be within the capabilities of a single center.
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The present pilot study was designed as a prospective, 
double-blind, parallel group, randomized trial to investigate 
the effects of  a combination of  DIP and ASA versus ASA 
alone on dyspnea, LV function, and exercise tolerance in 
patients with dilated cardiomyopathy (DCM).
MATERIALS AND METHODS
Study patients
DCM patients have been enrolled among those referring 
to the outpatient clinic of  the Department of  Internal 
Medicine for care and follow-up of  mild to moderate 
HF. Medical history was collected, and all participants 
underwent an office examination. The subjects were 
specifically asked about limitations of  physical activity, 
symptoms, dyspnea and discomfort during exertion, 
and status at rest. They were classified according to 
the New York Heart Association (NYHA) Functional 
Classification.[13]
Inclusion criteria were a global moderate to severe LV 
dysfunction (ejection fraction [EF], <40% by biplane 
area-length method on resting echocardiogram) but no 
history of  ischemic heart disease and angiographically 
normal coronary arteries (coronary angiogram performed 
prior to enrollment); NYHA Class II despite optimal 
medical therapy; clinical stability, defined as no change 
in therapy or symptoms and no hospital admission in 
the preceding 6 weeks; willingness to join the program. 
Exclusion criteria were symptomatic peripheral arterial 
disease, neoplastic disease, significant comorbidities 
reducing life expectancy to <1 year, serum creatinine 
>130 µmol/L, technically poor acoustic window precluding 
satisfactory imaging of  LV, inability to give informed 
consent, and contraindications to DIP therapy.
Patients were randomized to receive add-on, 6-month 
therapy either with ASA, 25 mg twice daily, or with 
ASA 25 mg plus slow-release DIP 200 mg twice daily 
(ASA + DIP). Medical therapy remained unchanged during 
the study. Both patients and investigators were unaware 
of  the treatment allocation. The subjects were examined 
at baseline, after 3 months, and after completion of  the 
6-month period.
The investigation complies with the principles outlined in 
the Declaration of  Helsinki. It was approved by the Local 
Ethics Committee, and all patients provided a written 
informed consent to participate.
Blood samples
A blood sample was taken from the antecubital vein on 
each morning of  the examination days, after an overnight 
fasting, for initial characterization of  the study population 
and follow-up.
Echocardiography
Transthoracic echocardiographic studies were performed 
with a Toshiba Aplio ultrasound device (Toshiba 
Medical Systems Europe, Zoetermeer, Netherlands) 
equipped with 2.5–3.5 MHz phased‑array sector scan 
probe (S3–S8 or V3–V7) and with the second harmonic 
technology. All standard echocardiographic views were 
obtained when possible. Atrial diameters were measured, 
and atrial volume was calculated by the prolate ellipse 
method, and then indexed to body surface area. LV 
end-diastolic and end-systolic diameters were measured 
from the M-mode trace obtained by parasternal long axis 
view. LV volumes were measured, and EF obtained by 
two-dimensional and four-chamber view using biplane 
area-length method, according to the recommendations 
of  the European Association of  Echocardiography.[14] 
LV mass was calculated by the Devereux formula[15] and 
indexed to body surface area. Mitral regurgitation was 
assessed semiquantitatively (from 1 to 4) by color flow 
Doppler. Mitral inflow pattern at the tips level was 
measured and E/A ratio computed.
Six-minute walk test
The 6-min walk test (6MWT) was performed according 
to the American Thoracic Society guidelines.[16] Briefly, 
all patients were instructed to cover the greatest distance 
possible on a level hallway during the allotted time at a 
self-determined walking speed, pausing to rest as needed, 
and the total distance in meters was recorded. Pulse 
oxygen saturation was measured by means of  a forehead 
probe connected to an oximeter (Nellcor N-595, Puritan 
Bennett, Pleasanton, CA, USA). Dyspnea at the end of  
the 6MWT was self-evaluated by means of  Borg scale that 
rates dyspnea perception and overall fatigue of  breathing 
from 0 (nothing at all) to 10 (very severe).[17]
Statistical analysis
Continuous variables in this analysis are expressed as 
median (25–75th percentile) and Mann–Whitney U-test 
was used to compare the characteristics between the two 
groups. Differences in categorical variables were compared 
by the Fisher’s exact test. General linear model ANOVA 
for repeated measures was used to evaluate the difference 
in changes in time between the two arms. A P < 0.05 was 
deemed significant. SPSS software, version 17.0.1 (SPSS 
Inc., Chicago, IL, USA) was used to perform all statistical 
analyses.
Sample size calculation
NYHA class, EF, meters walked at the 6MWT, and Borg 
scale after the test were the variables used to calculate an 
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adequate sample size for a possible larger trial, on the basis 
of  the results of  the present preliminary study. Clinically 
relevant changes were considered. Average difference of  
1 in NYHA classes, an absolute 5% variation in EF, 50 m 
at the 6MWT, and 1 point in the Borg scale. A statistical 
power of  90% with an alpha error of  5% was set.
RESULTS
The analysis was performed after the 21st recruited 
patient completed the 6-month follow-up period. Two 
of  the subjects did not complete the study, dropping 
after the baseline visit and before randomization: One 
for unwillingness to continue, the other due to relapse 
of  gynecological cancer. No participant reported serious 
adverse events during the intervention. Nineteen patients 
formed the final sample.
Eleven patients received ASA alone; eight in combination 
with DIP. In Table 1, the baseline clinical characteristics 
are reported. Table 2 shows echocardiographic parameters. 
Body weight and biochemical parameters did not differ 
between arms at any time point, neither changed over time 
(all P = not significant).
Both groups showed an improvement in exertional 
dyspnea of  daily life, i.e. a downward shift in NYHA class, 
without differences between the two treatment arms. After 
6 months, patients were n = 6/5/0/0 for NYHA Classes I/
II/III/IV in the ASA arm, n = 4/3/1/0 in the ASA + DIP 
arm [Figure 1].
EF increased significantly in both groups (from 34 [28–35%] 
to 40 [32–46%] for ASA, from 32.5 [25.75–34%] to 36 
[31.5–46%] for ASA + DIP at the end of  the study), without 
differences between arms [Figure 2]. The change was driven 
by a decrease in LV end-systolic diameter (P = 0.025) 
and volume (P = 0.016), while end-diastolic diameter and 
volume did not change (P = 0.81 and P = 0.64, respectively).
All patients were able to sustain the 6MWT. Pulse oxygen 
saturation remained normal (94–99%) for all subjects at 
all times, before and after the test. No change in exercise 
capacity and perceived exertion, measured, respectively, 
as meters walked, and points in the Borg scale was 
observed [Figures 3 and 4].
On the basis of  the mean values and variability of  
the chosen outcomes as they were measured in our 
study population, the sample size to detect meaningful 
differences in time and between arms was computed as a 
minimum of  8 subjects per arm for NYHA class, 17 for 
Table 1: Clinical characteristics of the study 
population
ASA ASA + DIP P
n=11 n=8
Sex, M/F 8/3 6/2 1.00
Age, years 55.7 (46.6-60.9) 59.6 (55.0-64.5) 0.25
Time since 
diagnosis, months
20 (11-72) 24 (11-35) 0.78
Hypertension, Y/N 6/5 5/3 1.00
Diabetes, Y/N 4/7 4/4 0.66
Therapy, Y/N
ACE-i or ARB 10/1 8/0 1.00
Beta-blockers 11/0 8/0 -
Diuretics 9/2 8/0 0.49
Digitalis 3/8 1/7 0.60
Nitrates 1/10 1/7 1.00
CCB 3/8 6/2 0.07
ASA 5/6 5/3 0.65
Statin 5/6 3/5 1.00
BMI, kg/m2 26.9 (24.5-30.6) 29.1 (25.0-31.8) 0.44
Na, mEq/L 141 (140-141.75) 143 (140.75-143.5) 0.09
K, mEq/L 4.55 (4.3-4.85) 4.20 (3.80-4.48) 0.21
Creatinine, mmol/L 75 (64.5-87) 83 (78-91) 0.17
Hb, g/dl 14.0 (13.15-14.65) 14.5 (14.5-14.6) 0.41
Total cholesterol, 
mmol/L
5.18 (4.94-6.40) 5.10 (4.27-5.85) 0.46
6-min walk test
Meters walked 390 (366.5-510) 367.5 (339.5-392.5) 0.25
Borg scale 2 (1-4.5) 2.5 (1-5) 0.87
Variables are median (25-75%) or dichotomized. ACE-i: Inhibitors of the angiotensin 
converting enzyme, ARB: Angiotensin receptor blocker, ASA: Acetylsalicylic 
acid, BMI: Body mass index, CCB: Calcium channel blockers, DIP: Dipyridamole, 
Hb: Hemoglobin, M/F: Male/female, Y/N: Yes/no
Table 2: Echocardiographic parameters at 
baseline
ASA ASA + DIP P
n=11 n=8
End-diastolic LV 
diameter, mm
69 (63.5-75) 69 (67.5-71.5) 0.87
End-systolic LV 
diameter, mm
60 (52.5-63.5) 58 (55-59.5) 0.87
End-diastolic LV 
volume, ml
242 (216-300) 245 (232-267.5) 0.68
End-systolic LV 
volume, ml
177 (132.5-189.5) 163 (151-171) 0.84
Ejection fraction, % 34 (28-35) 32.5 (25.75-34) 0.43
Left ventricular mass, g 201 (200-231) 257 (202-290) 0.46
Left ventricular mass 
index, g/m2
115 (102-121) 123 (101-144) 0.51
E/A 0.96 (0.77-1.46)* 0.59 (0.50-1.61)† 0.71
Mitral regurgitation, 1-4 2 (1.5-2) 1.5 (1-2) 0.27
Left atrial volume, ml 70 (63-102) 77 (68-92) 0.77
Left atrial volume 
index, ml/m2
41 (28-56) 42 (38-46) 0.92
Variables are median (25-75%). ASA: Acetylsalicylic acid, DIP: Dipyridamole, LV: Left 
ventricle. *Obtained in 10 subjects, †Obtained in 5 subjects
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EF, 12 for the 6MWT, and 12 for the Borg scale. Allowing a 
comparable drop-out rate (2 out of  21; 9.5%), the number 
of  subjects to recruit would increase to 9, 19, 14, and 14, 
respectively.
DISCUSSION
This pilot study was designed to investigate the clinical 
effect of  a 6-month course of  either ASA alone, or 
the commercially available combination of  ASA and 
extended‑release DIP, in patients with HF due to DCM. 
So far, the analyses did not show any significant difference 
between the two groups as regards to changes in clinical 
and echo parameters and exercise capacity. However, it has 
to be acknowledged that our sample is underpowered. On 
the basis of  these preliminary data, a properly sized trial 
adequately powered HF sample to test clinical and outcome 
end‑points and detect any significant variation in time and 
difference between arms would need the recruitment of  
at least 38 patients.
Rationale of the study
Adenosine, produced in cardiomyocytes and in endothelial cells, 
is known to be cardioprotective by targeting different receptors 
subtypes (A1, A2A, A2B, and A3).[4] Adenosine attenuates 
the release of  catecholamines, β-adrenoceptor-mediated 
myocardial hypercontraction, and calcium overload via 
A1 receptors. It also increases coronary blood flow and 
inhibits platelet and leukocyte activation via A2 receptors. 
Adenosine may exert antifibrotic and antiapoptotic 
effects.[18,19] Plasma adenosine levels are elevated,[3] and 
receptors are upregulated[20] in patients with HF. This led to 
hypothesize that the increase in adenosine could represent 
a compensatory mechanism and to speculate on a possible 
therapeutic use of  this molecule. However, due to the 
necessity of  intravenous administration, to extremely short 
half-life, and to severe side effects, exogenous adenosine as 
such has no role in chronic therapies.
Figure 1: New York Heart Association class. Mean values; error 
bars are ± standard error of the mean. Time effect: P = 0.005. Time x 
therapy: P = 0.56
Figure 2: Ejection fraction. Median values; error bars are 25–75%. 
Time effect: P = 0.003. Time x therapy: P = 0.83
Figure 3: Meters walked at the 6-min walk test. Median values; error 
bars are 25–75%. Time effect: P = 0.69. Time x therapy: P = 0.69
Figure 4: Borg score after the 6-min walk test. Median values; error 
bars are 25–75%. Time effect: P = 0.15. Time x therapy: P = 0.66
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DIP is a pyridopyrimidine compound with a complex 
and still partially unclear mechanism of  action. Among its 
effects – whose most known is the antiplatelet action – it 
inhibits adenosine reuptake thereby increasing the local 
and plasmatic concentration of  adenosine; it may have 
cardiac pro-angiogenic[21] as well as direct anti‑inflammatory 
properties. At present, DIP has two main clinical 
indications: (1) Intravenous high doses formulation for 
stress testing for coronary artery disease, an effect linked 
to the coronary vasodilatory effect;[22] (2) oral low dose, 
extended-release formulation, in combination with ASA, 
for secondary prophylaxis of  stroke.[23]
Clinical research concerning adenosine has usually looked 
for adenosine donors or receptor agonists. DIP has a 
limited marketing appeal for novel applications, since it is 
low‑cost and patent‑free, yet it has significant advantages 
when compared to new molecules. The drug has been on 
the market for 50 years and has an undisputed safety record, 
both at high intravenous doses and at low oral doses. It was 
largely used for the treatment of  myocardial infarction in 
the 1960s and 70s, in the absence of  any evidence-based 
proof  of  efficacy but with the robust empiric support of  
safety.
Some studies suggest that DIP therapy, resulting in an 
increase of  adenosine levels, may be beneficial in HF with 
ischemic heart disease.[24-27] Chronic oral administration 
of  sustained-release DIP has been reported to improve 
symptoms, exercise capacity, and LV function in patients 
with HF.[9-11] These studies are, however, limited by 
small sample size, variable dose range, heterogeneity of  
population, observational design, lack of  control group, 
nonrandomized allocation of  treatment, or absence of  
blinding procedures.
On the other hand, the PRoFESS study – a large, 
randomized clinical trial whose main aim was to compare 
clopidogrel to the combination of  ASA and DIP in 
secondary prevention of  stroke – observed, as a tertiary 
end‑point, a significant, unexpected, 30% reduction in 
the risk of  new or worsening HF with ASA plus DIP.[12] 
The explanation of  all these findings remains unsettled, 
but it may relate to the long-term positive effects of  
endogenous adenosine accumulation, possibly extended 
through an angiogenic, anti‑inflammatory, anti‑fibrotic, 
and anti-apoptotic effect.[28,29]
Comparison with previous studies
In this ad hoc, pilot study, both the ASA and the ASA + DIP 
groups increased in EF and decreased in NYHA. The 
change occurred in the ASA group is an unexpected result. 
It could be attributable to a combination of  placebo effect, 
regression to the mean, and better adherence to therapies 
in a drug trial setting. Moreover, studies on chronic HF 
should ideally be performed on “stable” patients, both 
from a clinical and pharmacological standpoint. Previous 
small‑scale studies on DIP and HF do not mention specific 
periods of  “stability” to enter the study; in the European 
HF guidelines, a stable patient is defined as having had no 
change in signs or symptoms for a month, but changes 
in therapy are not cited.[2] In the absence of  a univocal 
definition of  “stability,” one of  the inclusion criteria of  the 
present study was 6 weeks without changes in therapy or 
symptoms, but such a time could possibly not be enough, 
and in the study period patients could have shown a delayed 
benefit from drug therapies modified shortly before the 
term.
In the present study, the positive finding of  the improvement 
found in all key variables before and after DIP therapy 
turned into a neutral finding when the results in the control 
group – not available in the design of  previous positive 
reports[9,11] – were considered.
In former studies, benefits were already apparent also in 
shorter times, with lower DIP doses, or with a comparable 
number of  subjects. It has to be pointed out, however, that 
our investigation enrolled patients with DCM, excluding 
those with HF due to ischemic causes, while other dealt 
with mixed populations[9,11,12] or, on the contrary, specifically 
with ischemic patients.[10,26,27] These latter could particularly 
benefit from the known effect of  DIP on myocardial 
perfusion and coronary collateralization that is expected 
to play a minor role in DCM.
A feature only partially explained by the time the other 
studies were performed is the difference in therapies. There 
is heterogeneity in the use of  diuretics, digitalis, aldosterone 
antagonists, calcium channel blockers, nitrates, and 
anticoagulants; also beta-blockers, statins, and antiplatelet 
drugs are used unevenly, even in patients with myocardial 
ischemia. Some drugs, in particular calcium-antagonists, 
might have ancillary effect increasing plasma adenosine 
levels.[30] This could represent a confounder; in our study, 
patients had been on optimal medical therapy for at least 
6 weeks, and amlodipine was the only calcium-channel 
blocker employed.
Adenosine receptor polymorphisms can affect coronary 
flow reserve response during DIP stress testing;[31] 
differences in the genetic background could have influenced 
the response in our investigation, which dealt with small 
numbers and a particular ethnic group.[32,33]
Study limitations
The present study includes ASA in both treatment arms. 
This antiplatelet drug is not a standard therapy in HF, since 
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it has no evidence of  benefit, and although extensively used 
may raise harm concerns unless appropriately indicated.[1] 
Moreover, a proportion of  the subjects, similar in the two 
groups, was already taking ASA before entry. We cannot 
exclude a masking effect on the benefits of  DIP. A study 
about prevention of  cerebral ischemia with ASA (although 
at high dose) found no significant difference in HF 
occurrence between subjects taking also DIP and those 
who were not.[34] Furthermore, in the PRoFESS trial which 
is an important background to our study, the results were 
analyzed after a median follow-up of  2.5 years,[12] suggesting 
that the effects on HF may take longer than 6 months to 
show.
Additional benefits of  DIP are often attributed to its 
anti-inflammatory properties. We acknowledge that 
measuring inflammatory blood markers and relating 
them and their changes to clinical effects would have 
been interesting.[35] Furthermore, as plasma adenosine 
was not measured, it is not known if  the same dose of  
DIP turned out in comparable increases in all patients 
of  the ASA + DIP arm, which were only eight. This 
introduces the most obvious limitation of  the study: The 
small sample size. It was basically due to lack of  external 
funding, which led to restrictions in recruitment but also 
to the obvious advantage of  a nonprofit, curiosity‑driven 
investigation without the possible bias due to industry 
funding. The stringent selection criteria excluding patients 
with ischemic disease, the randomized, double-blind, 
and placebo-controlled study design allowed to obtain a 
methodologically sound information.
CONCLUSION
This pilot study did not confirm, so far, a beneficial role 
on symptoms, exercise capacity or systolic function of  
DIP plus ASA, compared to the latter drug alone, in DCM 
patients. The findings are however to be considered with 
caution. The data have barely enough statistical power 
to adequately test the NYHA outcome only – a rather 
subjective measure.
The lack of  benefit at this point may appear in contrast 
with previous studies, but the strict inclusion criteria, 
the randomized, double-blind design, and the use of  
well-established clinical end-points give strength to these 
preliminary findings. The present study could guide 
other investigators in designing new trials with larger 
samples – but well within the recruitment capability of  a 
single center – and/or longer follow-ups allowing changes 
in heart function and hemodynamics to become effective, 
to shed light on a possible role of  DIP in the management 
of  nonischemic HF.
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